NL9002092A - Vaccin, geschikt voor de bestrijding van bordetella pertussis. - Google Patents

Vaccin, geschikt voor de bestrijding van bordetella pertussis. Download PDF

Info

Publication number: NL9002092A
Authority: NL; Netherlands
Prior art keywords: pertussis; omvs; omp; vaccine; vaccine according
Prior art date: 1990-09-25

Application number

NL9002092A

Other languages

English (en)

Dutch (nl)

Original Assignee

Nederlanden Staat

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-09-25

Filing date

1990-09-25

Publication date

1992-04-16

1990-09-25 Application filed by Nederlanden Staat filed Critical Nederlanden Staat

1990-09-25 Priority to NL9002092A priority Critical patent/NL9002092A/nl

1991-09-25 Priority to EP91919318A priority patent/EP0550683B1/en

1991-09-25 Priority to PCT/NL1991/000185 priority patent/WO1992005194A1/en

1991-09-25 Priority to DK91919318.5T priority patent/DK0550683T3/da

1991-09-25 Priority to CA002092420A priority patent/CA2092420C/en

1991-09-25 Priority to DE69109126T priority patent/DE69109126T2/de

1991-09-25 Priority to ES91919318T priority patent/ES2073180T3/es

1991-09-25 Priority to AT91919318T priority patent/ATE121423T1/de

1992-04-16 Publication of NL9002092A publication Critical patent/NL9002092A/nl

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 63
241000588832 Bordetella pertussis Species 0.000 title claims abstract description 50
239000000203 mixture Substances 0.000 claims abstract description 11
201000005702 Pertussis Diseases 0.000 claims abstract description 8
238000009472 formulation Methods 0.000 claims abstract description 8
241000040340 Oat mosaic virus Species 0.000 claims description 25
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 17
239000002158 endotoxin Substances 0.000 claims description 17
229940009976 deoxycholate Drugs 0.000 claims description 13
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 13
238000002360 preparation method Methods 0.000 claims description 13
108090000623 proteins and genes Proteins 0.000 claims description 13
238000000034 method Methods 0.000 claims description 4
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 2
238000010353 genetic engineering Methods 0.000 claims description 2
229910052588 hydroxylapatite Inorganic materials 0.000 claims description 2
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 2
238000002255 vaccination Methods 0.000 claims description 2
238000004587 chromatography analysis Methods 0.000 claims 1
230000002588 toxic effect Effects 0.000 claims 1
101710116435 Outer membrane protein Proteins 0.000 abstract description 63
239000003599 detergent Substances 0.000 abstract description 7
239000012528 membrane Substances 0.000 abstract description 4
244000005700 microbiome Species 0.000 abstract 1
108010081690 Pertussis Toxin Proteins 0.000 description 32
239000000427 antigen Substances 0.000 description 22
108091007433 antigens Proteins 0.000 description 22
102000036639 antigens Human genes 0.000 description 22
238000012360 testing method Methods 0.000 description 14
241000699670 Mus sp. Species 0.000 description 13
241000894006 Bacteria Species 0.000 description 12
235000018102 proteins Nutrition 0.000 description 12
102000004169 proteins and genes Human genes 0.000 description 12
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
210000004027 cell Anatomy 0.000 description 10
IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 10
239000006228 supernatant Substances 0.000 description 9
241000699666 Mus <mouse, genus> Species 0.000 description 8
241001197446 Mus cypriacus Species 0.000 description 8
239000007983 Tris buffer Substances 0.000 description 8
230000000694 effects Effects 0.000 description 8
238000002965 ELISA Methods 0.000 description 7
238000005119 centrifugation Methods 0.000 description 7
229920006008 lipopolysaccharide Polymers 0.000 description 7
229940066827 pertussis vaccine Drugs 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
239000008188 pellet Substances 0.000 description 6
229910001629 magnesium chloride Inorganic materials 0.000 description 5
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
229920004890 Triton X-100 Polymers 0.000 description 4
239000013504 Triton X-100 Substances 0.000 description 4
239000002253 acid Substances 0.000 description 4
239000000872 buffer Substances 0.000 description 4
229940030156 cell vaccine Drugs 0.000 description 4
230000012010 growth Effects 0.000 description 4
238000011160 research Methods 0.000 description 4
239000000725 suspension Substances 0.000 description 4
101710154643 Filamentous hemagglutinin Proteins 0.000 description 3
241000588677 Neisseria meningitidis serogroup B Species 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
210000004408 hybridoma Anatomy 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000002649 immunization Methods 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000000693 micelle Substances 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
239000002504 physiological saline solution Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
210000002345 respiratory system Anatomy 0.000 description 3
239000000243 solution Substances 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241000606768 Haemophilus influenzae Species 0.000 description 2
101710164702 Major outer membrane protein Proteins 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
102000003992 Peroxidases Human genes 0.000 description 2
206010037660 Pyrexia Diseases 0.000 description 2
JQYMGXZJTCOARG-UHFFFAOYSA-N Reactive blue 2 Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC(S(O)(=O)=O)=C1 JQYMGXZJTCOARG-UHFFFAOYSA-N 0.000 description 2
239000012506 Sephacryl® Substances 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
210000004081 cilia Anatomy 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
229940047650 haemophilus influenzae Drugs 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
235000001968 nicotinic acid Nutrition 0.000 description 2
229960003512 nicotinic acid Drugs 0.000 description 2
239000011664 nicotinic acid Substances 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
239000000047 product Substances 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
RCLDHCIEAUJSBD-UHFFFAOYSA-N 6-(6-sulfonaphthalen-2-yl)oxynaphthalene-2-sulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=CC2=CC(OC3=CC4=CC=C(C=C4C=C3)S(=O)(=O)O)=CC=C21 RCLDHCIEAUJSBD-UHFFFAOYSA-N 0.000 description 1
108010049290 ADP Ribose Transferases Proteins 0.000 description 1
102000009062 ADP Ribose Transferases Human genes 0.000 description 1
229910017119 AlPO Inorganic materials 0.000 description 1
238000000035 BCA protein assay Methods 0.000 description 1
239000001987 Bordet-Gengou agar Substances 0.000 description 1
241000588807 Bordetella Species 0.000 description 1
241000917014 Bordetella pertussis 18323 Species 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
206010011469 Crying Diseases 0.000 description 1
229920002271 DEAE-Sepharose Polymers 0.000 description 1
208000032274 Encephalopathy Diseases 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
BFVQTKQTUCQRPI-YYEZTRBPSA-N LPS with O-antigen Chemical compound O([C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]5[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O5)O)O4)O)[C@@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)NC(C)=O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)OC([C@@H]1O)O[C@H]1[C@H](O)[C@@H]([C@@H](O)COC2[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O2)O)OC([C@H]1O)O[C@H]1[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)OC([C@H]1O)O[C@H]1[C@H](O[C@]2(O[C@@H]([C@@H](O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)C[C@](O[C@@H]1[C@@H](O)CO)(OC[C@H]1O[C@@H](OC[C@@H]2[C@H]([C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O2)O)[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]1OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O BFVQTKQTUCQRPI-YYEZTRBPSA-N 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
208000008784 apnea Diseases 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000006931 brain damage Effects 0.000 description 1
231100000874 brain damage Toxicity 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
229960000878 docusate sodium Drugs 0.000 description 1
238000002635 electroconvulsive therapy Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
102000013361 fetuin Human genes 0.000 description 1
108060002885 fetuin Proteins 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000009533 lab test Methods 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
229960005030 other vaccine in atc Drugs 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
229940016590 sarkosyl Drugs 0.000 description 1
108700004121 sarkosyl Proteins 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
238000012807 shake-flask culturing Methods 0.000 description 1
APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
229940079862 sodium lauryl sarcosinate Drugs 0.000 description 1
ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
230000009466 transformation Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

NL9002092A 1990-09-25 1990-09-25 Vaccin, geschikt voor de bestrijding van bordetella pertussis. NL9002092A (nl)

Priority Applications (8)

Application Number	Priority Date	Filing Date	Title
NL9002092A NL9002092A (nl)	1990-09-25	1990-09-25	Vaccin, geschikt voor de bestrijding van bordetella pertussis.
EP91919318A EP0550683B1 (en)	1990-09-25	1991-09-25	Vaccine suitable for combatting bordetella pertussis
PCT/NL1991/000185 WO1992005194A1 (en)	1990-09-25	1991-09-25	Vaccine suitable for combatting bordetella pertussis
DK91919318.5T DK0550683T3 (da)	1990-09-25	1991-09-25	Vaccine egnet til bekæmpelse af Borderella pertussis
CA002092420A CA2092420C (en)	1990-09-25	1991-09-25	Vaccine suitable for combatting bordetella pertussis
DE69109126T DE69109126T2 (de)	1990-09-25	1991-09-25	Impfstoff, geeignet für die bekämpfung von bordetella pertussis.
ES91919318T ES2073180T3 (es)	1990-09-25	1991-09-25	Vacuna adecuada para combatir la bacteria bordetella pertussis.
AT91919318T ATE121423T1 (de)	1990-09-25	1991-09-25	Impfstoff, geeignet für die bekämpfung von bordetella pertussis.

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
NL9002092A NL9002092A (nl)	1990-09-25	1990-09-25	Vaccin, geschikt voor de bestrijding van bordetella pertussis.
NL9002092		1990-09-25

Publications (1)

Publication Number	Publication Date
NL9002092A true NL9002092A (nl)	1992-04-16

Family

ID=19857724

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL9002092A NL9002092A (nl)	1990-09-25	1990-09-25	Vaccin, geschikt voor de bestrijding van bordetella pertussis.

Country Status (8)

Country	Link
EP (1)	EP0550683B1 (es)
AT (1)	ATE121423T1 (es)
CA (1)	CA2092420C (es)
DE (1)	DE69109126T2 (es)
DK (1)	DK0550683T3 (es)
ES (1)	ES2073180T3 (es)
NL (1)	NL9002092A (es)
WO (1)	WO1992005194A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5156958A (en) *	1990-09-21	1992-10-20	American Cyanamid Company	Gene encoding a 30 kilodalton outer membrane protein of bordetella pertussis and method of recombinant production of said protein
BR9609882A (pt) *	1995-08-04	1999-07-27	Univ Guelph	Vacina processos para preparar a mesma para tratar uma doença infecciosa para inserir uma molécula de ácido nucleico em uma célula de marcaç o para administrar um agente terapêutico a um hospedeiro e para triar um antígeno imunogênico de um patógeno uso de uma vesícula de membrana composição farmacêutica sistema de liberação de drogas e vesícula de membrana
US20020028215A1 (en)	1999-08-09	2002-03-07	Jagath L. Kadurugamuwa	Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
FR2754543B1 (fr) *	1996-10-11	1998-12-31	Pasteur Institut	Souche de bordetella deficiente dans la production de toxine et exprimant une proteine hydride, liposomes comprenant de la fha et leurs utilisations comme vaccins, et utilisation de la fha pour stimuler les reponses immunitaires
FR2805163A1 (fr) *	2000-02-21	2001-08-24	Pf Medicament	Utilisation d'un detergent de type zwittergent pour la preparation d'une composition pharmaceutique destinee a etre administree par voie nasale
GB0416120D0 (en)	2004-07-19	2004-08-18	Health Prot Agency	Stable compositions containing OMV's

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU5432690A (en) *	1989-03-31	1990-11-05	Washington University	Bordetella vaccines
GB9007657D0 (en) *	1990-04-04	1990-05-30	Connaught Lab	Purification of a pertussis outer membrane protein(omp69)

1990
- 1990-09-25 NL NL9002092A patent/NL9002092A/nl not_active Application Discontinuation
1991
- 1991-09-25 EP EP91919318A patent/EP0550683B1/en not_active Expired - Lifetime
- 1991-09-25 DE DE69109126T patent/DE69109126T2/de not_active Expired - Fee Related
- 1991-09-25 CA CA002092420A patent/CA2092420C/en not_active Expired - Fee Related
- 1991-09-25 WO PCT/NL1991/000185 patent/WO1992005194A1/en active IP Right Grant
- 1991-09-25 DK DK91919318.5T patent/DK0550683T3/da active
- 1991-09-25 ES ES91919318T patent/ES2073180T3/es not_active Expired - Lifetime
- 1991-09-25 AT AT91919318T patent/ATE121423T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
ES2073180T3 (es)	1995-08-01
DK0550683T3 (da)	1995-09-04
DE69109126D1 (de)	1995-05-24
ATE121423T1 (de)	1995-05-15
CA2092420A1 (en)	1992-03-26
EP0550683B1 (en)	1995-04-19
DE69109126T2 (de)	1995-09-21
WO1992005194A1 (en)	1992-04-02
EP0550683A1 (en)	1993-07-14
CA2092420C (en)	1999-11-23

Legal Events

Date	Code	Title	Description
1992-04-16	A1B	A search report has been drawn up
1996-06-03	BV	The patent application has lapsed

Publication	Publication Date	Title
Andrews et al.	1996	Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge
Sjöstedt et al.	1992	Humoral and cell-mediated immunity in mice to a 17-kilodalton lipoprotein of Francisella tularensis expressed by Salmonella typhimurium
Martin et al.	1997	Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection
Urisu et al.	1986	Filamentous hemagglutinin has a major role in mediating adherence of Bordetella pertussis to human WiDr cells
Shahin et al.	1992	Mucosal immunization with filamentous hemagglutinin protects against Bordetella pertussis respiratory infection
JP2002541808A (ja)	2002-12-10	ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
EP0453024B1 (en)	1995-05-31	Actinobacillus pleuropneumoniae subunit vaccine
Dabo et al.	2008	Vaccination with Pasteurella multocida recombinant OmpA induces strong but non-protective and deleterious Th2-type immune response in mice
JP2690215B2 (ja)	1997-12-10	無細胞抗百日咳菌ワクチン
US7902349B2 (en)	2011-03-08	Nucleic acids encoding protective epitopes of adenyl cyclase-haemolysin (AC-Hly)
Finn et al.	1991	Characterization of vir-activated TnphoA gene fusions in Bordetella pertussis
EP0815236B1 (en)	2004-12-22	Haemophilus adhesion proteins
NL9002092A (nl)	1992-04-16	Vaccin, geschikt voor de bestrijding van bordetella pertussis.
PT90310B (pt)	1994-09-30	Processo para a obtencao de preparacoes de adenilato-ciclase
AU725137B2 (en)	2000-10-05	Bordetella strain expressing the hybrid FHA, liposomes and vaccines
Hamstra et al.	1995	The purification and protective capacity of Bordetella pertussis outer membrane proteins
Angelos et al.	2016	Systemic and ocular immune responses in cattle following intranasal vaccination with precipitated or partially solubilized recombinant Moraxella bovis cytotoxin adjuvanted with polyacrylic acid
JPH10510984A (ja)	1998-10-27	無細胞性抗ボルデテラワクチン
US20020172691A1 (en)	2002-11-21	Use of adenylate cyclase or bacteria producing it as vaccines against bordetella
Martin et al.	1986	A common neisserial antigen evidenced by immunization of mice with live Neisseria meningitidis
Cripps et al.	1992	Respiratory immunity stimulated by intestinal immunization with purified nontypeable Haemophilus influenzae antigens
Sánchez et al.	2002	Interspecific neisserial high molecular weight proteins able to induce natural immunity responses are strongly correlated with in vitro bactericidal activity
KR100258772B1 (ko)	2000-08-01	돼지의 흉막폐염 백신 조성물
Isibasi et al.	1988	The role of outer membrane proteins from gram-negative bacteria as VACCINES with special emphasis in typhoid fever: monoclonal antibodies against S. typhi porins
Webb et al.	1988	Approaches to the rational design of bacterial vaccines